Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-12-17
2009-02-03
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S062000
Reexamination Certificate
active
07485629
ABSTRACT:
The invention provides compositions useful for the treatment and/or prevention of damage to diarthrodial (synovial) joints and, in particular, traumatic synovitis, inflammation of the synovial membrane, and damage to the articular cartilage of the joint. Specifically, provided are compositions specially formulated for intra-articular and/or parenteral use in the treatment and/or prevention of traumaticsynovitis and/or damage to articular cartilage. Compositions adapted specifically for post surgical joint lavage or treatment and/or prevention of inflammatory arthritis, osteoarthritis (OA) and/or degenerative joint disease (DJD) are also provided. Compositions adapted for intra-articular and/or systemic administration comprised of therapeutic amounts of: chondroitin sulfate and hyaluronan (hyaluronic acid) are provided.
REFERENCES:
patent: 3683076 (1972-08-01), Rovati
patent: 3697652 (1972-10-01), Rovati et al.
patent: 4782046 (1988-11-01), Brown et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4870061 (1989-09-01), Speck
patent: 5364845 (1994-11-01), Henderson
patent: 5587363 (1996-12-01), Henderson
patent: 5840715 (1998-11-01), Florio
patent: 5916565 (1999-06-01), Rose et al.
patent: 5922692 (1999-07-01), Marino
patent: 6255295 (2001-07-01), Henderson et al.
patent: 6432929 (2002-08-01), Stone
patent: 6476005 (2002-11-01), Petito
patent: 6492349 (2002-12-01), Henderson
patent: 6506785 (2003-01-01), Evans et al.
patent: 6608041 (2003-08-01), Hammerly
patent: 6645482 (2003-11-01), Theoharides
patent: 6906044 (2005-06-01), Hermida
patent: 6949525 (2005-09-01), Hermida
patent: 6979679 (2005-12-01), Marcum
patent: 2002/0068718 (2002-06-01), Pierce
patent: 2317109 (1998-03-01), None
patent: 2317109 (1998-03-01), None
patent: WO 01/32188 (2001-05-01), None
patent: WO 03/041724 (2003-06-01), None
Dorna and Guerrero, Journal of Equine Veterinary Science 1998, vol. 18, No. 9, abstract only.
Bassleer et al., 1998, “Stimulation of Proteglycan Production by Glucosamine Sulfate in Chondrocytes Isolated from Human Osteoarthritic Articular Cartilage in Vitro,” Osteoarthritis and Cartilage, vol. 6, pp. 427-434.
Bucci et al., 1994, “Glucosamine Salts and Chondroitin Sulfates,” Townsend Letter for Doctors, pp. 52-54.
Capps et al., 1966, “Hexosamine Metabolism,” Biochimica et Biophysica ACTA, 127:194-204.
Coleman et al., 1999, “Characterization of the Effect of High Molecular Weight Hyaluronan on Trans-Synovial Flow in Rabbit Knees,” Journal of Physiology, 514.1, pp. 265-282.
Coleman et al., 1997, “Hyaluronan Secretion into the Synovial Cavity of Rabbit Knees and Comparison with Albumin Turnover,” Journal of Physiology, 503.3, pp. 645-656.
Coleman et al., 2000, “Role of Hyaluronan Chain Length in Buffering Interstitial Flow Across Synovium in Rabbits,” Journal of Physiology, 526.2, pp. 425-434.
Day et al., 2002, “Hyaluronan-Binding Proteins: Tying up the Giant,” The Journal of Biological Chemistry, vol. 277, No. 7, pp. 4585-4588.
Dorna et al., 1998, “Effects of Oral and Intramuscular Use of Chondroitin Sulfate in Induced Equine Aseptic Arthritis.”
Hinderlich et al., 2000, “Molecular Cloning and Characterization of Murine and Human N-acetylglucosamine Kinase,” Eur. J. biochem., 267:3301-3308.
Johnson et al., 2001, “Chondroitin Sulfate,” Continuing Education Module from the New Hope Institute of Retailing.
McIlwraith, “Traumatic Joint Injuries and Disease,” http://www.equineortho.colostate.edu/questions/tjd.htm.
Murray M.:“Glucosamine sulfate: effective osteoarthritis treatment.” Amer. J. Nat. Med. 1994; Sep. 10-14.
Sabaratnam et al., 2002, “Interactive Effect of Chondroitin Sulphate C and Hyaluronan on Fluid Movement Across Rabbit Synovium,” Journal of Physiology, 540.1, pp. 271-284.
Schiavinato et al., 2002, “Comparison of the Effects of Intra-Articular Injections of Hyaluronan and Its Chemically Cross-Linked Derivative (Hylan G-F20) in Normal Rabbit Knee Joints,” Clinical and Experimental Rheumatology, 20:445-454.
Shikhman et al., 2001, “N-Acetylglucosamine Prevents IL-1beta-Mediated Activation of Human Chondrocytes,” The American Association of Immunologists.
Tersariol et al., 2002, “Proteinase Activity Regulation by Glycosaminoglycans,” Brazilian Journal of Medical and Biological Research, 335:135-144.
Tesoriere et al., 1972, “Intestinal Absorption of Glucosamine and N-Acetylglucosamine,” Experientia 28:770-1.
Todhunter et al., 1993, “Effects of Exercise and Polysulfated Glycosaminoglycan on Repair of Articular Cartilage Defects in the Equine Carpus,” Journal of Orthopaedic Research, 11:782-795.
Heart et al., 2002, “Glucose Transport by Osmotic Shock and Vanadate is Impaired by Glucosamine,” Biochem Biophys Res Commun; 292:308-11.
de Mattei et al., 2002, “High Doses of Glucosamine-HC1 have Detrimental Effects on Bovine Articular Cartilage Explants Cultured in vitro,” Osteoarthritis-Cartilage.; 10(10):816-25.
Breborowicz et al., 1998, “The effect of N-acetylglucosamine as a substrate for in vitro synthesis of glycosaminoglycans by human peritoneal mesothelial cells and fibroblasts,” Adv Perit Dial; 14:31-5.
Vide;a Doma I. DVM and C. Guerrero DVM, Effects of Oral and Intramuscular use of Chondroitin Sulfate in Induced Equine Aseptic Arthritis, Journal of Equine Veterinary Science, Sep. 1998.
ArthroDynamic Technologies, Animal Health Division, Inc.
Bland Layla
Jiang Shaojia Anna
Sutherland & Asbill & Brennan LLP
LandOfFree
Composition and method for treatment of joint damage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treatment of joint damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treatment of joint damage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4137154